Trial · NCT07368543
Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer
NCT07368543, Phase 2, Not yet recruiting, Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer. Trials, record NCT07368543. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07368543
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer
- NCT number
- NCT07368543
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 216 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- Metastatic Breast Cancer
- Interventions
- Sacituzumab Govitecan, Trastuzumab Deruxtecan
- First posted
- 2026-01-26
- Last updated
- 2026-01-28
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival 1 (PFS1) | Until progression, assessed up to approximately 24 months | Progression-Free Survival 1 (PFS1):Time from the initiation of the first ADC (ADC1) therapy to the first occurrence of disease progression (PD) or death from any cause, whichever occurs earlier. |
| Secondary | Progression-Free Survival 2 (PFS2) | Until progression, assessed up to approximately 24 months | Progression-Free Survival 2 (PFS2): Time from initiation of the second ADC (ADC2) therapy to the first occurrence of disease progression (PD) or death from any cause, whichever occurs earlier. |
| Secondary | Objective Response Rate (ORR1, ORR2) | Until progression, assessed up to approximately 24 months | Objective Response Rate (ORR1, ORR2): Proportion of patients with best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1 criteria. |
| Secondary | Disease Control Rate (DCR | Baseline through end of study, assessed up to 24 months] | Disease Control Rate (DCR): Proportion of patients with best overall response of CR, PR, or stable disease (SD) according to RECIST 1.1 criteria. |
| Secondary | Overall Survival (OS) | Until death, assessed up to approximately 24 months | Overall Survival (OS): Time from treatment initiation to death from any cause. |
| Secondary | Safety Endpoints | Up to follow-up period, approximately 24 months] | Safety Endpoints: Include adverse event profiles, incidence rates, dose reductions, treatment delays, and discontinuations due to adverse events. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07368543
GET https://conductscience.org/api/trials/v1/NCT07368543/registered